Platelet-Rich Plasma in Cardiovascular Regeneration: Mechanistic Insights, Technological Innovations, and Future Directions.

IF 1.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Reviews in cardiovascular medicine Pub Date : 2025-07-28 eCollection Date: 2025-07-01 DOI:10.31083/RCM39383
Ju Tian, Jing Chen, Xiuling Lai, Jing Ding, Jie Sun, Dandan Shi, Xiaoying He, Xingqi Chen
{"title":"Platelet-Rich Plasma in Cardiovascular Regeneration: Mechanistic Insights, Technological Innovations, and Future Directions.","authors":"Ju Tian, Jing Chen, Xiuling Lai, Jing Ding, Jie Sun, Dandan Shi, Xiaoying He, Xingqi Chen","doi":"10.31083/RCM39383","DOIUrl":null,"url":null,"abstract":"<p><p>Platelet-rich plasma (PRP), an autologous concentrate of platelets and bioactive molecules, has emerged as a promising regenerative therapy in cardiovascular medicine. The potential of PRP extends beyond hemostasis to include myocardial repair, angiogenesis, and immunomodulation. This review explores the biological mechanisms of PRP, its clinical applications in ischemic heart disease, peripheral artery disease, and inflammatory cardiopathies, and addresses challenges in standardization and translation. PRP exerts therapeutic effects through three primary mechanisms: promoting angiogenesis by stimulating endothelial cell proliferation and migration, exerting anti-inflammatory and immunomodulatory effects by balancing cytokine release, and enhancing myocardial repair and functional recovery by activating resident cardiac progenitor cells. Despite the promise of PRP, challenges such as variability in PRP composition due to differences in preparation methods and safety concerns remain. To overcome these barriers, precision engineering and cross-disciplinary integration are crucial. Innovations such as nanotechnology-driven targeted delivery systems and clustered regularly interspaced short palindromic repeats (CRISPR)-edited exosomes offer mechanism-specific interventions. Artificial intelligence (AI)-driven approaches utilizing single-cell RNA sequencing data can enable personalized treatment strategies, while closed-loop systems minimize batch-to-batch variability. Collaborative efforts between clinicians, engineers, and regulators are essential to establish global standards for exosome characterization. PRP-based therapies hold immense promise for revolutionizing cardiovascular regenerative medicine by modulating angiogenesis, inflammation, and myocardial repair. By embracing these advanced technologies and interdisciplinary approaches, PRP can transition from an empirical treatment to a data-driven, mechanism-specific intervention, ultimately redefining the future of cardiovascular care.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 7","pages":"39383"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12326410/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in cardiovascular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/RCM39383","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Platelet-rich plasma (PRP), an autologous concentrate of platelets and bioactive molecules, has emerged as a promising regenerative therapy in cardiovascular medicine. The potential of PRP extends beyond hemostasis to include myocardial repair, angiogenesis, and immunomodulation. This review explores the biological mechanisms of PRP, its clinical applications in ischemic heart disease, peripheral artery disease, and inflammatory cardiopathies, and addresses challenges in standardization and translation. PRP exerts therapeutic effects through three primary mechanisms: promoting angiogenesis by stimulating endothelial cell proliferation and migration, exerting anti-inflammatory and immunomodulatory effects by balancing cytokine release, and enhancing myocardial repair and functional recovery by activating resident cardiac progenitor cells. Despite the promise of PRP, challenges such as variability in PRP composition due to differences in preparation methods and safety concerns remain. To overcome these barriers, precision engineering and cross-disciplinary integration are crucial. Innovations such as nanotechnology-driven targeted delivery systems and clustered regularly interspaced short palindromic repeats (CRISPR)-edited exosomes offer mechanism-specific interventions. Artificial intelligence (AI)-driven approaches utilizing single-cell RNA sequencing data can enable personalized treatment strategies, while closed-loop systems minimize batch-to-batch variability. Collaborative efforts between clinicians, engineers, and regulators are essential to establish global standards for exosome characterization. PRP-based therapies hold immense promise for revolutionizing cardiovascular regenerative medicine by modulating angiogenesis, inflammation, and myocardial repair. By embracing these advanced technologies and interdisciplinary approaches, PRP can transition from an empirical treatment to a data-driven, mechanism-specific intervention, ultimately redefining the future of cardiovascular care.

富血小板血浆在心血管再生中的应用:机制、技术创新和未来发展方向。
富血小板血浆(PRP)是一种血小板和生物活性分子的自体浓缩物,已成为心血管医学中一种很有前途的再生疗法。PRP的潜在作用不仅限于止血,还包括心肌修复、血管生成和免疫调节。本文综述了PRP的生物学机制、在缺血性心脏病、外周动脉疾病和炎症性心脏病中的临床应用,以及在标准化和翻译方面面临的挑战。PRP主要通过三个机制发挥治疗作用:通过刺激内皮细胞增殖和迁移促进血管生成,通过平衡细胞因子释放发挥抗炎和免疫调节作用,通过激活常驻心脏祖细胞促进心肌修复和功能恢复。尽管PRP前景光明,但由于制备方法和安全问题的差异,PRP成分的可变性等挑战仍然存在。为了克服这些障碍,精密工程和跨学科整合至关重要。诸如纳米技术驱动的靶向递送系统和聚集规律间隔短回文重复(CRISPR)编辑的外泌体等创新提供了机制特异性干预。利用单细胞RNA测序数据的人工智能(AI)驱动的方法可以实现个性化的治疗策略,而闭环系统则可以最大限度地减少批次间的差异。临床医生、工程师和监管机构之间的合作努力对于建立外泌体表征的全球标准至关重要。基于prp的疗法通过调节血管生成、炎症和心肌修复,对心血管再生医学的革命有着巨大的希望。通过采用这些先进技术和跨学科方法,PRP可以从经验治疗转变为数据驱动的机制特异性干预,最终重新定义心血管护理的未来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reviews in cardiovascular medicine
Reviews in cardiovascular medicine 医学-心血管系统
CiteScore
2.70
自引率
3.70%
发文量
377
审稿时长
1 months
期刊介绍: RCM is an international, peer-reviewed, open access journal. RCM publishes research articles, review papers and short communications on cardiovascular medicine as well as research on cardiovascular disease. We aim to provide a forum for publishing papers which explore the pathogenesis and promote the progression of cardiac and vascular diseases. We also seek to establish an interdisciplinary platform, focusing on translational issues, to facilitate the advancement of research, clinical treatment and diagnostic procedures. Heart surgery, cardiovascular imaging, risk factors and various clinical cardiac & vascular research will be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信